Back to top
more

Ono Pharmaceutical Co. (OPHLF)

(Delayed Data from OTC)

$14.47 USD

14.47
9

0.00 (0.00%)

Updated Apr 25, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for OPHLF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Ono Pharmaceutical Co falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 1,216 1,041 987 924
Receivables NA 847 888 792 707
Notes Receivable NA 0 0 0 0
Inventories NA 332 372 368 303
Other Current Assets NA 160 202 181 139
Total Current Assets NA 2,554 2,503 2,328 2,072
Net Property & Equipment NA 802 998 1,070 1,055
Investments & Advances NA 2,374 2,247 2,621 2,111
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 263 223 316 320
Intangibles NA 512 576 661 611
Deposits & Other Assets NA 25 32 24 26
Total Assets NA 6,530 6,579 7,020 6,196
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 494 442 368 317
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 256 14 179 187
Other Current Liabilities NA 141 110 315 316
Total Current Liabilities NA 910 587 881 840
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 7 9 10 10
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 30 36 36 63
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 996 690 993 970
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 128 154 163 160
Capital Surplus NA 126 153 162 159
Retained Earnings NA 5,253 5,738 5,484 4,826
Other Equity NA 427 507 638 493
Treasury Stock NA 401 665 420 412
Total Shareholder's Equity NA 5,534 5,889 6,027 5,226
Total Liabilities & Shareholder's Equity NA 6,530 6,579 7,020 6,196
Total Common Equity 0 5,534 5,889 6,027 5,226
Shares Outstanding NA 514.10 514.10 NA 514.10
Book Value Per Share 0.00 10.76 11.45 -0.06 10.16

Fiscal Year End for Ono Pharmaceutical Co falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 974 940 1,216
Receivables NA NA 978 902 847
Notes Receivable NA NA NA 0 0
Inventories NA NA 335 368 332
Other Current Assets NA NA 165 171 160
Total Current Assets NA NA 2,451 2,381 2,554
Net Property & Equipment NA NA 731 785 802
Investments & Advances NA NA 2,322 2,440 2,374
Other Non-Current Assets NA NA NA 0 0
Deferred Charges NA NA 242 247 263
Intangibles NA NA 417 493 512
Deposits & Other Assets NA NA 19 19 25
Total Assets NA NA 6,182 6,365 6,530
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA 0 0
Accounts Payable NA NA 366 379 494
Current Portion Long-Term Debt NA NA NA 0 0
Current Portion Capital Leases NA NA NA 0 0
Accrued Expenses NA NA NA 0 0
Income Taxes Payable NA NA 177 81 256
Other Current Liabilities NA NA 138 191 141
Total Current Liabilities NA NA 697 668 910
Mortgages NA NA NA 0 0
Deferred Taxes/Income NA NA 7 7 7
Convertible Debt NA NA NA 0 0
Long-Term Debt NA NA NA 0 0
Non-Current Capital Leases NA NA NA 0 0
Other Non-Current Liabilities NA 27 29 30
Minority Interest (Liabilities) NA NA NA 0 0
Total Liabilities NA NA 777 755 996
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA 0 0
Common Stock (Par) NA NA 120 127 128
Capital Surplus NA NA 118 125 126
Retained Earnings NA NA 5,295 5,283 5,253
Other Equity NA NA 433 470 427
Treasury Stock NA NA 561 395 401
Total Shareholder's Equity NA NA 5,405 5,610 5,534
Total Liabilities & Shareholder's Equity NA NA 6,182 6,365 6,530
Total Common Equity 0 0 105,404 5,610 5,534
Shares Outstanding NA NA NA NA 514.10
Book Value Per Share 0.00 0.00 -1.05 -0.06 10.76